Butyrate for Gut Epithelial Health — Gut
Short-chain fatty acid (SCFA) that is the primary energy source for colonocytes, with moderate evidence for gut barrier function and anti-inflammatory effects.
Overview
Butyrate (butyric acid, C4:0) is a four-carbon short-chain fatty acid (SCFA) produced by bacterial fermentation of dietary fiber in the colon. It is the primary energy source for colonocytes, providing approximately 70% of their metabolic fuel through beta-oxidation. Butyrate plays a central role in maintaining colonic epithelial integrity, immune homeostasis, and anti-inflammatory signaling. Its mechanisms of action are multifaceted: it is a potent histone deacetylase (HDAC) inhibitor, promoting epigenetic changes that suppress pro-inflammatory gene expression (NF-kB pathway) while upregulating anti-inflammatory cytokines (IL-10) and regulatory T cell differentiation. Butyrate also activates G-protein-coupled receptors GPR41, GPR43, and GPR109A on intestinal epithelial and immune cells, modulating gut hormone release (GLP-1, PYY) and immune function. Clinical studies demonstrate that butyrate supplementation improves symptoms of ulcerative colitis, reduces intestinal permeability, and supports gut barrier function. Butyrate enemas have been used in diversion colitis and ulcerative proctitis with documented mucosal healing. Oral sodium butyrate (300-600 mg/day) and tributyrin (a butyrate prodrug with better gastric stability) are available as supplements. Low butyrate-producing gut microbiota are consistently associated with inflammatory bowel disease, metabolic syndrome, and colorectal cancer risk.
Indications
- Moderate evidence: Colonic epithelial health and gut barrier function
- Moderate evidence: Ulcerative colitis adjunctive therapy (oral and enema)
- Moderate evidence: Reduced intestinal permeability (leaky gut)
- Emerging evidence: Metabolic health (GLP-1, PYY stimulation)
- Emerging evidence: Immune modulation (regulatory T cell induction)
- Preclinical: Colorectal cancer chemoprevention (HDAC inhibition)
Mechanism of Action
Butyrate is preferentially oxidized by colonocytes through beta-oxidation, providing ~70% of their energy and maintaining the physiologic oxygen gradient that supports anaerobic microbiota
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Sodium butyrate (enteric-coated) | 300 mg | Three times daily with meals | Standard dose for gut health support |
| Sodium butyrate (enteric-coated) | 600 mg | Three times daily | Higher dose for IBD adjunctive support |
| Tributyrin (CoreBiome / ProButyrate) | 500-1000 mg | Twice daily with meals | Butyrate prodrug; better tolerated and absorbed |
| Sodium butyrate enema | 100 mM in 60 mL saline | Once daily or twice daily | Direct colonic delivery for UC/proctitis; Rx compounded |
Evidence Grade
GRADE C
Safety & Contraindications
- Generally well tolerated at standard supplemental doses (300-600 mg/day sodium butyrate)
- GI symptoms (bloating, gas, nausea) possible, especially at initiation
- Sodium butyrate has an extremely unpleasant odor — enteric-coated capsules recommended
- Tributyrin (butyrate prodrug) has better palatability and gastric stability
- Very high doses may cause hyperosmolar diarrhea
- No significant drug interactions documented at standard doses